Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish · 2018
DOI: 10.1177/2284240318792449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2018. Verfasst von Dario Lidonnici und 6 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Objectives
To describe the length of time taken by the Italian Medicines Agency (AIFA) to formulate pricing and reimbursement decisions for drugs approved via centralized procedures and to evaluate possible differences between categories of drugs (innovative drugs, oncological and rare disease drugs, products negotiated with Managed Entry Agreements and/or managed via registry).
Methods
Monthly meeting reports of the Technical Scientific Committee (CTS) and the Price and Reimbursement Committee (CPR) as well European and Italian Official Journals were scrutinized from January 2015 to January 2018.
Results
In the scrutinized period, 85 out of 190 drugs obtained reimbursement and were included in the analysis. Overall, time-to-market (CTS assessment opening to Official Journal) was 258 days. About one third of the whole procedure was dedicated to administrative steps, without significant differences between drug categories.
Conclusions
Our analysis shows that transparency makes it possible to determine the length of time taken by AIFA to conclude the Price and Reimbursement (P&R) process. It also suggests that administrative procedures may still be optimized to allow faster access to treatments for patients and provides a starting point to determine future policies in this area.
Zitieren
APA
Lidonnici, D., Ronco, V., Isernia, M., Lanati, E., Jommi, C., Canonico, P. L., & Genazzani, A. A. (2018). Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. https://doi.org/10.1177/2284240318792449
Vancouver
Lidonnici D, Ronco V, Isernia M, Lanati E, Jommi C, Canonico PL, et al. Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2018. doi:10.1177/2284240318792449
BibTeX
@article{Lidonnici2018,
author = {Lidonnici, Dario and Ronco, Virginia and Isernia, Martina and Lanati, Elena and Jommi, Claudio and Canonico, Pier Luigi and Genazzani, Armando A.},
title = {Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco},
journal = {Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish},
year = {2018},
doi = {10.1177/2284240318792449}
}
EUVIMED